54 Results for "

cdk4/cyclin D

" in MedChemExpress (MCE) Product Catalog:
Products (54)

54 Results for "cdk4/cyclin D" in MCE Product Catalog:

7
7 Publications Verification
Cat. No.: HY-10424
CAS No.: 802539-81-7
Purity:  99.90%
Synonyms: PHA-848125
Target:  

CDK Autophagy

Research Areas:  

Cancer

Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.
loading...
    loading...
7
7 Publications Verification
Cat. No.: HY-11009
CAS No.: 164658-13-3
Purity:  98.90%
Target:  

CDK PKC

Research Areas:  

Cancer

CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC50 values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-18299A
CAS No.: 212844-53-6
Synonyms: NG-60
Target:  

CDK Autophagy Apoptosis

Research Areas:  

Cancer

Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15504A
CAS No.: 784210-88-4
Purity:  98.02%
Target:  

CDK GSK-3 MEK JAK

Research Areas:  

Cancer

RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC50s of 3, 5, 50, and 54 nM.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15504
CAS No.: 784210-87-3
Purity:  99.70%
Target:  

CDK GSK-3 MEK JAK

Research Areas:  

Cancer

RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC50s of 3, 5, 50, and 54 nM.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-16559
CAS No.: 920113-03-7
Synonyms: P276-00
Target:  

CDK Apoptosis

Research Areas:  

Cancer

Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively . Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-18981
CAS No.: 5928-25-6
Synonyms: (+)-Decursin
Decursin ((+)-Decursin) is a potent anti-tumor agent. Decursin also is a cytotoxic agent and a potent protein kinase C activator. Decursin induces apoptosis and cell cycle arrest at G1 phase. Decursin decreases the expression of CDK2, CDK4, CDK6, cyclin D1 protein at 48 h. Decursin inhibits cell proliferation and migration. Decursin shows anti-tumor, anti-inflammatory and analgesic activities .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-10014
CAS No.: 741713-40-6
Purity:  99.57%
Target:  

CDK GSK-3 Apoptosis

Research Areas:  

Cancer

R547 is a potent, selective and orally active ATP-competitive CDK inhibitor, with Kis of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-111361
CAS No.: 1429515-59-2
Purity:  98.72%
Synonyms: LT-171-861
Target:  

CDK FLT3

Research Areas:  

Cancer

FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N7045
CAS No.: 142796-22-3
Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce cyclins (D3, D1, A, E), Cdk4, Cdk2, Cdc25A), and activate Caspases (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-103380
CAS No.: 141992-47-4
Purity:  98.58%
Target:  

CDK

Research Areas:  

Cancer

NSC 625987 is a specific and high-affinity CDK4 inhibitor with an IC50 of 0.2 μM for CDK4:cyclin D1. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P702682
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: cdk4; cyclin-Dependent Kinase 4; cyclin Dependent Kinase 4; cyclin-Dependent Kinase; PSK-J3; MCPH31; Cell Division Protein Kinase 4; CMM3; CCND1; B-Cell CLL/Lymphoma 1; Prev. PRAD1; PRAD1 Oncogene; Prev. BCL1; Parathyroid Adenomatosis 1; Prev. D11S287E; C
Species:  
Source:  
loading...
    loading...
Cat. No.: HY-103382
CAS No.: 118458-54-1
Purity:  99.8%
Arcyriaflavin A is an indolo[2,3-a]carbazole compound and also a cyclin D1/CDK4 inhibitor. Arcyriaflavin A exists in the marine ascidian Eudistoma sp. and the slime mold Arcyria denudata. Arcyriaflavin A is applicable to research related to colon cancer and lung cancer .
loading...
    loading...
Cat. No.: HY-15777S
CAS No.: 1328934-40-2
Synonyms: LEE011-d6
Ribociclib-d6 (LEE011-d6) is a deuterium labeled Ribociclib (HY-15777). Ribociclib is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .
loading...
    loading...
Cat. No.: HY-122620
CAS No.: 2114365-78-3
Purity:  98.33%
Synonyms: Hetrombopag (tautomerism); SHR-8735 (tautomerism)
Rafutrombopag (tautomerism) (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
loading...
    loading...
Cat. No.: HY-136726
CAS No.: 359886-84-3
Purity:  98.12%
Synonyms: CINK4
Target:  

CDK

Research Areas:  

Cancer

GP-82996 (CINK4) is a pharmacological inhibitor of CDK4/6. GP-82996 has IC50s of 1.5, 5.6 and 25 μM for CDK4/cyclin D1, CDK6/cyclin D1 and Cdk5/p35, respectively. GP-82996 induces the apoptosis of cancer cells U2OS. GP-82996 can be used in the research of cancer .
loading...
    loading...
Cat. No.: HY-15777AS
CAS No.: 2934109-69-8
Purity:  98.26%
Synonyms: LEE011-d6 hydrochloride
Ribociclib-d6 (LEE011-d6) hydrochloride is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex .
loading...
    loading...
Cat. No.: HY-15612
CAS No.: 1256963-02-6
Target:  

CDK

Research Areas:  

Cancer

CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.
loading...
    loading...
Cat. No.: HY-145589
CAS No.: 2600513-51-5
Synonyms: Hetrombopag; SHR-8735
Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
loading...
    loading...
Cat. No.: HY-P1109
CAS No.: 189064-08-2
Target:  

CDK

Research Areas:  

Cancer

[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a (p16) tumor suppressor protein. [Ala92]-p16 (84-103) binds to both cdk4 and cdk6 and inhibits cdk4-cyclin D1 kinase activity in vitro (IC50: 1.5 μM). [Ala92]-p16 (84-103) blocks cell cycle progression through the G1 phase .
loading...
    loading...